microsimulation model (Credence Genomics)
90
Structured Review
Credence Genomics
microsimulation model
Microsimulation Model, supplied by Credence Genomics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microsimulation+models/microsimulation+model/pm38960842-75-7-22
Average 90 stars, based on 1 article reviews
Microsimulation Model, supplied by Credence Genomics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microsimulation+models/microsimulation+model/pm38960842-75-7-22
Average 90 stars, based on 1 article reviews
microsimulation model - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium. Article Snippet: Objectives: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial showed reduced renal and cardiovascular (CV) events in patients with type 2 diabetes (T2D) and diabetic kidney disease (DKD) treated with canagliflozin 100 mg added to Standard of Care (SoC) versus SoC alone.. This led to an extension of the canagliflozin 100 mg European marketing authorisation, making canagliflozin the first pharmacological therapy to receive authorisation for the treatment of DKD since the RENAAL and IDNT trials more than 20 years ago.. Given the importance of cost-effectiveness analyses in health care, this study aimed to leverage the CREDENCE trial outcomes to estimate the costeffectiveness of canagliflozin 100 mg from the perspective of the Belgian healthcare system. |